RPEP-12934 · 2025CKD doubled heart failure event rates, but tirzepatide benefits were consistent across kidney function levels. Creatinine-based and cystatin C-based eGFR gave discordant results.
Pandey, Ambarish; Moroney, Michael; Verma, Subodh; Borlaug, Barry A; Butler, Javed; Davies, Melanie J; Kitzman, Dalane W; Shah, Sanjiv J; Petrie, Mark C; Rönnbäck, Cecilia; Domdey, Anne; Rasmussen, Søren; Chinnakondepalli, Khaja M; Patel, Shachi; Kosiborod, Mikhail N · Secondary Analysis
RPEP-12935 · 2025Semaglutide's efficacy in obesity-related HFpEF was consistent across frailty subgroups, and semaglutide treatment itself improved frailty status — a novel and clinically significant finding.
Pandey, Ambarish; Kitzman, Dalane W; Chinnakondepalli, Khaja M; Patel, Shachi; Borlaug, Barry A; Butler, Javed; Davies, Melanie J; Shah, Sanjiv J; Verma, Subodh; Rönnbäck, Cecilia; Domdey, Anne; Liisberg, Karoline; Schou, Morten; Perna, Eduardo; Ahmed, Fozia Z; Fu, Michael; Petrie, Mark C; Kosiborod, Mikhail N · Secondary Analysis
RPEP-12936 · 2025Meta-analysis confirmed orforglipron's efficacy for weight reduction and glycemic control in obese adults with or without T2DM, with a safety profile consistent with the GLP-1 drug class.
Pandey, Ravi Kumar; Jan, Mahnoor; Mohammad, Aqsa; Jawaid, Khawaja Arham; Naveed, Mawra; Abid, Muhammad Ali; Amir, Abdullah Bin; Ahmed, Shafique; Safiullah, Muhammad; Bhatti, Muhammad Imaz; Iftikhar, Sana; Saddique, Muhammad Nabeel; Alfalh, Widyan; Omar, Rihab Mohammed Bin; Abu Dawood, Husam · Meta Analysis
RPEP-12937 · 2025PRRT triggered an acute ACTH-mediated hypercortisolemic crisis in a patient with ectopic Cushing syndrome, with cortisol reaching 141 µg/dL (normal: 5-25 µg/dL) and ACTH >2000 pg/mL, requiring emergency management.
Pandit, Raghavendra; Yamichannaiah, Chethan; Lila, Anurag Ranjan; Karlekar, Manjiri; Memon, Saba Samad; Bandgar, Tushar · Case Report
RPEP-12938 · 2025Stability-optimized melittin variants maintained anti-inflammatory activity while resisting protease degradation, significantly reducing ulcerative colitis severity in a mouse model.
Pang, Cheng-Jian; Yao, Jing-Fang; Lv, Qiu-Lan; Zhang, Li-Ze; Yu, Qian-Yao; Zeng, Li; Qi, Yun-Kun · Animal Study
RPEP-12939 · 2025PLGA/HA nanoparticles loaded with liraglutide provided sustained local release that reduced diabetic periodontitis severity by inhibiting necroptosis in periodontal tissues, addressing both glycemic control and local tissue destruction.
Pang, Yunqing; Kong, Lingyuan; Li, Yuanyuan; Li, Jiamin; Ma, Qianlong; Qiu, Jing; Wang, Jing · Animal Study
RPEP-12940 · 2025The triple-component hydrogel (RGD@DEXMA/DOPA-P24/Mn3O4) synergistically reduced ROS-driven inflammation, promoted M1-to-M2 macrophage polarization and angiogenesis, and enhanced osteogenic differentiation of bone marrow stem cells, accelerating bone defect regeneration in vivo.
Pang, Yuxuan; Wang, Xin; Zhang, Huan; Li, Xin; Lin, Min; Cheng, Liang; Yang, Ying-Wei · Animal Study
RPEP-12941 · 2025αCGRP deficiency did not change overall cartilage degradation scores but prevented cartilage extracellular matrix stiffening, altered subchondral bone remodeling, caused trabecular bone loss with intense exercise, and elevated proinflammatory serum markers—establishing αCGRP as a key mediator of joint and bone responses to mechanical stress during OA.
Pann, Patrick; Kalke, Paul; Maier, Verena; Schäfer, Nicole; Clausen-Schaumann, Hauke; Schilling, Arndt F; Grässel, Susanne · Animal Study
RPEP-12942 · 2025Natriuretic peptides act as multisystem regulators with natriuretic, vasodilatory, antifibrotic, and immunomodulatory effects via cGMP-PKG signaling, but their therapeutic potential is limited by NP resistance mechanisms including neprilysin degradation, NPR-C clearance, and receptor desensitization in advanced disease.
Panneflek, Jathniel; Barbarawi, Mahmoud; Kakarlapudi, Yasitha; Barbarawi, Zaid; Lauzea, Béatrice; Meraz-Torres, Manolo · Narrative Review
RPEP-12943 · 2025Healthy human platelets express RAS receptors (Mas, MrgD, ACE, ACE2, AT1, AT2) but angiotensin peptides (Ang-I, Ang-II, Ang-(1-7), Ang-(1-9), alamandine) had no effect on platelet adhesion or aggregation at any concentration tested. ACE activity was present but captopril-resistant; ACE2 was undetectable.
Panosetti, François; Cuenot, François M; Saint Auguste, Damian S; Martins Cavaco, Ana C; Nunes, Allancer D C; Lu, Philip H J; Magrini, Céline; Molot, Max; Sanglard, Gabriel; Günçü, Rodi; Zouaghi, Yassine; Béguelin, Charles; Martins Lima, Augusto; Stergiopulos, Nikolaos · In Vitro
RPEP-12944 · 2025GLP-1RAs reduced ferroptosis markers (decreased ACSL4, increased protective factors) comparably to ferrostatin-1 and suppressed pyroptosis markers (caspase-1, GSDMD, IL-1β, NLRP3) in experimental models of diabetic kidney disease and metabolic liver disease, with additional anti-inflammatory, anti-fibrotic, and antioxidant effects.
Panou, Theodoros; Gouveri, Evanthia; Rizzo, Manfredi; Popovic, Djordje S; Papanas, Nikolaos · Narrative Review
RPEP-12945 · 2025Orforglipron achieved HbA1c reductions of up to 2.10%, weight loss up to 13.0 kg (obesity) or 10.1 kg (T2DM), waist circumference reductions up to 8.7 cm, and significant blood pressure decreases. Meta-analyses ranked it the most efficient GLP-1RA for weight loss.
Panou, Theodoros; Gouveri, Evanthia; Popovic, Djordje S; Papanas, Nikolaos · Narrative Review
RPEP-12946 · 2025Clinical studies show GLP-1RAs and dual GLP-1/GIP agonists can cause significant lean mass loss and sarcopenia risk, but preclinical evidence paradoxically shows these agents may attenuate skeletal muscle atrophy, improve muscle function, and enhance mitochondrial health at the cellular level.
Pantazopoulos, Dimitrios; Gouveri, Evanthia; Papazoglou, Dimitrios; Papanas, Nikolaos · Narrative Review
RPEP-12947 · 2025Non-peptide GnRH antagonists combine the benefits of rapid onset (no flare-up effect), oral administration, and dose-dependent estrogen suppression, offering advantages over both GnRH agonists (delayed onset, injection required) and peptide antagonists (injection required) for endometriosis treatment.
Paoletti, Anna Maria; Neri, Manuela; Pilloni, Monica; Marotto, Maria Francesca; Giancane, Elena; Vallerino, Valerio; Piras, Bruno; Melis, Giulia; Melis, Virginia; Masciale, Michele Danilo Maria; Murgia, Enrica; Melis, Gian Benedetto · Narrative Review
RPEP-12948 · 2025Lean MASLD is mechanistically distinct from obesity-related MASLD, driven by bile acid dysregulation, leptin signaling abnormalities, and oxidative stress. Animal models testing GLP-1 analogues (exendin-4, liraglutide), kinsenoside, silibinin, and bile acid modulators show therapeutic promise for this patient population.
Papadakos, Stavros P; Georgiadou, Chara; Kassi, Eva; Velliou, Rallia-Iliana; Chatzigeorgiou, Antonios · Narrative Review
RPEP-12949 · 2025Hypoalbuminemia (HR 0.91 per unit) and elevated CRP (HR 1.02 per unit) independently predicted shorter overall survival in PRRT-treated NET patients. GPS score of 2 vs. 0 had HR 3.60. Albumin was the single most valuable addition to established prognostic models, while dNLR added no value.
Papantoniou, Dimitrios; Fröss-Baron, Katarzyna; Garske-Román, Ulrike; Sundin, Anders; Thiis-Evensen, Espen; Grönberg, Malin; Welin, Staffan; Tiensuu Janson, Eva · Retrospective Cohort
RPEP-12950 · 2025Tirzepatide cost €5,646 vs semaglutide €3,202 over 72 weeks. Semaglutide showed numerically lower cost per responder at ≥10% weight loss; tirzepatide was favored at ≥25-30% targets. Probabilistic analysis showed no statistically significant difference at any threshold.
Papantoniou, Panagiotis; Maniadakis, Nikolaos · Cost Effectiveness Analysis
RPEP-12951 · 2025Semaglutide 2.4 mg yielded an ICER of €12,724 per QALY gained versus liraglutide 3 mg. In probabilistic sensitivity analysis, semaglutide dominated liraglutide (higher QALYs at lower cost) in 80.8% of simulations and reached 100% cost-effectiveness probability at a €9,000/QALY threshold.
Papantoniou, Panagiotis; Maniadakis, Nikolaos · Cost Effectiveness Analysis
RPEP-12952 · 2025Hyperinsulinemic obesity decreased trabecular and cortical bone thickness with BMAT expansion but preserved CRAMP levels. Insulinopenic T2D decreased trabecular number, impaired bone stiffness, and reduced circulating CRAMP peptide levels, suggesting a link between insulin deficiency, bone quality, and innate immune peptide regulation.
Paquet, Amélie; Bahlouli, Nadia; Coutel, Xavier; Leterme, Damien; Delattre, Jérôme; Gauthier, Véronique; Miellot, Flore; Delplace, Séverine; Rouge-Labriet, Hélène; Bertheaume, Nicolas; Chauveau, Christophe; Benachour, Hamanou · Animal Study
RPEP-12953 · 2025RAMP1 expression was associated with reduced survival in CRC and GC. Over 50% of CRC and 60% of GC cells expressed RAMP1. Tumor cells themselves produced CGRP (not just nerves). CGRP stimulation enhanced tumor growth in a RAMP1-dependent manner, activating proliferation, metabolism, and migration pathways.
Parathan, Pavitha; Tran, Kelly; Neil, Liam; Tan, Tao; Carli, Annalisa L E; Liao, Yang; Mouradov, Dmitri; Da Gama Duarte, Jessica; Huber, Anne; Pal, Bhupinder; Gibbs, Peter; Sieber, Oliver M; Chiu, Isaac M; Kearney, Conor J; Shi, Wei; Mariadason, John M; Williams, David S; Buchert, Michael; Mielke, Lisa A · Observational
RPEP-12954 · 2025After switching from dulaglutide to semaglutide, patients achieved additional HbA1c reductions of -0.43% (6 mo), -0.54% (12 mo), -0.38% (18 mo), and additional weight loss of -2.7 kg (6 mo), -3.7 kg (12 mo), -5.4 kg (18 mo), -4.2 kg (24 mo), with no significant increase in adverse effects.
Pardo Lozano, Felipe; Rubio Marcos, Arantxa; Casañ Fernández, Rosa; Bartual Rodrigo, Amparo; Martínez-Hervás, Sergio; Ampudia-Blasco, Francisco Javier · Observational
RPEP-12955 · 2025PRRT toxicities are stratified into acute (nausea, hormone-related crises), subacute (bone marrow suppression, kidney effects), and long-term (renal impairment, myelodysplastic syndrome). Most side effects are transient, but awareness of high-risk factors is essential for prevention and early management.
Parghane, Rahul V; Basu, Sandip · Narrative Review
RPEP-12956 · 2025Prior GLP-1 agonist use showed no association with adverse ICU outcomes: in-hospital mortality 5.1% vs 4.9% (OR 1.05, 95% CI 0.58-1.91), hospital LOS 13.7 vs 13.4 days, ICU LOS 5.9 vs 5.4 days. All differences were non-significant.
Park, Albert K; Hom, Jason; Lorenzo, Javier; Rao, Vidya; Hui, Gavin; Vickers, Matthew; Ahuja, Neera · Retrospective Cohort
RPEP-12957 · 2025Semaglutide increased VR cells +34.8% (vs +0.8% usual care, p=0.036), endothelial precursors +66.2% (vs -2.3%, p=0.037), and reduced granulocyte precursors -50.8% (vs +0.3%, p=0.002). Pro-inflammatory TNF and interleukin serum proteins were also downregulated.
Park, Brady; Dennis, Fallon; He, Arianna Z; Krishnaraj, Aishwarya; Bakbak, Ehab; Dennis, Cole J; Pan, Yi; Misner, Elizabeth; Thayanithy, Veena; Lambotharan, Bhavaani; Lambotharan, Vaasudevan; Lambotharan, Aruna; Mazer, C David; Quan, Adrian; Teoh, Hwee; Hess, David A; Verma, Subodh · Randomized Controlled Trial
RPEP-12958 · 2025Sugar glider cathelicidins reside in two genomic clusters, are highly expressed in neonatal neutrophils, have potent antibacterial activity, modulate immune responses, and provide sufficient protection against sepsis in a mouse model. Marsupials and monotremes uniquely retain both genomic clusters among tetrapods.
Park, Jongbeom; Ke, Wenfan; Kaage, Aellah; Feigin, Charles Y; Griffing, Aaron H; Pritykin, Yuri; Donia, Mohamed S; Mallarino, Ricardo · Animal Study
RPEP-12959 · 2025PN5 demonstrated dual-function activity: direct bactericidal membrane disruption against MDR S. Typhimurium plus immune modulation via NF-κB and MAPK pathways. It eliminated intracellular bacteria in macrophages, inhibited biofilm formation, and significantly improved survival in a murine infection model.
Park, Jonggwan; Kang, Da Dam; Kim, Hyeongsun; Oh, Jun Hee; Park, Yoonkyung · Animal Study
RPEP-12960 · 2025Liraglutide 3.0 mg reduced AST from 33.2 to 27.4 IU/L (p<0.001), ALT from 41.6 to 30.6 IU/L (p<0.001), HSI from 44.7 to 42.2 (p<0.001), and NAFLD liver fat score from 2.12 to 0.43 (p<0.001) over 6 months. Insulin sensitivity improved from 4.38 to 4.72 (p<0.001).
Park, Jungha; Kim, Jin-Wook; Lim, Soo · Observational
RPEP-12961 · 2025CAMP is overexpressed in cSCC and promotes tumor growth via FPRL1 receptor. S1P signaling drives CAMP production; inhibiting S1P reduces CAMP-stimulated cSCC growth. CAMP increases FOXP3+ regulatory T cells (suppressing anti-tumor immunity) and induces ER stress, creating a vicious S1P-CAMP feedback loop that favors cSCC development.
Park, Kyungho; Shin, Kyong-Oh; Kim, Young-Il; Nielsen-Scott, Anna L; Mainzer, Carine; Celli, Anna; Bae, Yoojin; Chae, Seungwoo; An, Hahyun; Choi, Yerim; Park, Jae-Ho; Park, Soo-Hyun; Hwang, Jin-Taek; Kang, Seung Goo; Wakefield, Joan S; Arron, Sarah T; Holleran, Walter M; Mauro, Theodora M; Elias, Peter M; Uchida, Yoshikazu · In Vitro
RPEP-12962 · 2025All 11 CF patients lost weight (median -7.2 kg). 8/11 improved FEV1 (up to +18%), 9/11 improved FVC (up to +26%). All 7 with CFRD reduced insulin (mean -31.5% total daily dose). Glucose time in range improved (mean +11%).
Park, Sanghoon; Jain, Raksha; Mirfakhraee, Sasan · Case Series
RPEP-12975 · 2025Protein-peptide complexes demonstrated ability to heal epithelial barriers, suppress pro-inflammatory cytokines (TNF-α, IL-13, IL-17), and restore gut microbiota balance in preclinical UC models.
Patel, Alka; Jain, Parag; Ajazuddin · Narrative Review
RPEP-12976 · 2025Corin and furin show altered expression across different heart failure phenotypes, offering mechanistic insight into disease progression, though their diagnostic performance remains modest compared to BNP and NT-proBNP.
Patel, Dhruvil Vinaybhai; Patel, Sanket; Acharya, Sankalp; Raol, Karanrajsinh · Narrative Review
RPEP-12977 · 2025The peptide amphiphile hydrogel successfully transitioned from 1D nanofiber networks to 0D micelles, functioning as cell-penetrating peptides while providing temporal control of ciprofloxacin release over 48 hours. The formulation was non-cytotoxic to epidermal keratinocytes.
Patel, Evan A; Shah, Swapnil V; Poulson, Trevor A; Fry, H Christopher; Jagasia, Ashok A · In Vitro
RPEP-12978 · 2025All four agents provide weight loss benefits through distinct mechanisms. GLP-1 agonists (semaglutide, liraglutide) show superior efficacy but cause GI side effects. Orlistat reduces fat absorption with GI discomfort. Phentermine suppresses appetite but has dependency potential. Emerging dual/triple agonists show promise.
Patel, Jay P; Hardaswani, Daksh; Patel, Jaykumar; Saiyed, Faizanali; Goswami, Rushita J; Saiyed, Taskin I; Patel, Harshkumar; Amin, Trishul H · Systematic Review
RPEP-12979 · 2025Dulaglutide re-initiation at a higher dose triggered euglycemic DKA presenting with GI symptoms and weakness. Normal blood glucose levels made diagnosis challenging. Resolved with insulin drip and IV fluids.
Patel, Niyati; Reddy, Anvit; Romero, Kaitlyn N; Reddy, Pramod · Case Report
RPEP-12980 · 2025In STEP-HFpEF and SUMMIT trials, semaglutide and tirzepatide achieved 13.3% and 13.9% weight reduction, 21.5m and 26m improvements in 6MWD, 19.5 and 16.6 point KCCQ-CSS improvements, and 38.8% and 43.5% CRP reductions in obese HFpEF patients.
Patel, Ravi; Kokori, Emmanuel; Olatunji, Gbolahan; Adejumo, Faith Adedayo; Ukah, Joan Dumebi; Babalola, Adetola Emmanuel; Ndakotsu, Andrew; Abraham, Israel Charles; Aderinto, Nicholas · Narrative Review
RPEP-12981 · 2025Long-standing twice-daily withdrawal symptoms from larotrectinib (myalgias, arthralgias, photosensitivity occurring 30-45 min before doses) completely resolved after semaglutide initiation in a patient with >7 years of TRK inhibitor therapy.
Patel, Reema; Deeken, John F · Case Report
RPEP-12982 · 2025Semaglutide reduced alcohol use; dulaglutide lowered intake in current drinkers; exenatide showed no significant effect on heavy drinking days. Three RCTs reviewed (n=48-151).
Patel, Sheel; Blaney, Hanna; Nassar, Sarah; Singal, Ashwani K · Systematic Review
RPEP-12983 · 2025GLP-1 RAs achieve HbA1c reductions of 1.5-2.0%, weight loss of 7-24%, and 14-20% MACE reduction. Pleiotropic mechanisms include mitochondrial function enhancement, anti-inflammatory effects, and cellular quality control improvement. Emerging applications span neurology, dermatology, respiratory, addiction, and autoimmune fields.
Patel, Shikha; Niazi, Sarfaraz K · Systematic Review
RPEP-12984 · 2025After 3 months of tirzepatide, significant reductions in weight, BMI, WC, WtHR, BRI, and VAI (all p<0.05). PREDIMED scores increased +3.2 points (p<0.001). Higher Mediterranean diet adherence independently associated with lower insulin, improved HOMA, and greater VAI reduction.
Paternò, Valentina; Geraci, Giulio; Piticchio, Tommaso; Le Moli, Rosario; Burgio, Stefano; Costanzo, Gabriele; Sambataro, Gianluca; Baratta, Roberto; Barbagallo, Federica; Pallotti, Francesco · Observational
RPEP-12985 · 2025Peptide stapling via hydrocarbon staples, lactam bridges, and metal-coordination bonds enhances peptide stability, bioavailability, cellular penetration, and target binding affinity for antiviral applications against neurotropic viruses including HSV and influenza.
Patil, Sanskruti; Rahangdale, Rakesh; Pasupuleti, Mukesh; Santhoshkumar, Puttur; Hariharapura, Raghu Chandrashekar · Narrative Review
RPEP-12986 · 2025Exenatide vs placebo over 16 weeks: -0.5 kg (-0.6%) vs +2.6 kg (+2.8%), both p<0.01. Exenatide was well-tolerated. No clinically meaningful differences in mood or psychotic symptoms between groups.
Patino, Luis R; Strawn, Jeffrey R; Adler, Caleb M; Blom, Thomas J; Welge, Jeffrey A; DelBello, Melissa P · Randomized Controlled Trial
RPEP-12987 · 2025PRRT with Lu-177 DOTATATE resolved hypoglycemia in 93% of patients (14/15) after a median of 2.5 months, with median overall survival of 50.1 months and successful re-treatment in all recurrence cases.
Pattison, David A; Kong, Grace; Akhurst, Timothy; Burge, Matthew; Chiang, Cherie; Hofman, Michael S; Hung, Te-Jui; Love, Amanda; Michael, Michael; Okano, Satomi; Ravi Kumar, Aravind S; Sachithanandan, Nirupa; Wyld, David; Hicks, Rodney J · Retrospective Cohort
RPEP-12988 · 2025Exenatide reduced lipedema symptoms, evoked pain, and ultrasound-measured subcutaneous fat thickness in legs, abdomen, and arms, including in patients without weight loss.
Patton, Laura; Reverdito, Valeria; Bellucci, Alessandra; Bortolon, Micaela; Macrelli, Annalisa; Ricolfi, Lorenzo · Case Series
RPEP-12989 · 2025A multi-epitope vaccine candidate was designed using subtractive proteomics and immunoinformatics targeting essential hypothetical proteins of antibiotic-resistant B. subvibrioides.
Paul, Ishani; Roy, Alankar; Sarkar, Tista; Dutta, Shounak; Ray, Sujay · Computational
RPEP-12990 · 2025BNP and NT-proBNP levels may be normal in HFpEF patients due to reduced myocardial wall stress, increased peptide clearance, and medication effects, creating a significant diagnostic gap.
Paul, Tyler; Nadeem, Amin Ur Rehman; Naqvi, Syed M; Liu, Jason; Ali, Khaled A · Case Report
RPEP-12991 · 2025Lisinopril produced the strongest antihypertensive effect; dual RAS blockade created complex angiotensin peptide profile changes but only modest additional blood pressure reduction in this low-RAS model.
Paulis, L; Rajkovicova, R; Repova, K; Gubo, G; Barta, A; Poglitsch, M; Domenig, O; Andelova, N; Ferko, M; Pechanova, O; Simko, F · Animal Study
RPEP-12992 · 2025Approximately half of itch-responsive PBN-CeA projecting neurons are CGRP+, and optogenetic stimulation of these neurons elicits scratching behavior without enhancing anxiety in mice.
Pavlenko, Darya; Ishida, Hirotake; Markan, Anika; Akiyama, Tasuku · Animal Study
RPEP-12993 · 2025Semaglutide use in a post-Roux-en-Y gastric bypass patient led to intussusception with small bowel obstruction and chemical pancreatitis requiring surgical intervention.
Pavuluri, Suresh K; Toumar, Ahmad; Duffy, Andrew J · Case Report
RPEP-12994 · 2025High-fructose diets induced synaptic and neuronal adaptations at hypothalamic NPY/AgRP neurons, promoting hyperphagia and fat gain with sex-dependent metabolic effects.
Payant, Mikayla A; Sankhe, Aditi S; Miller, Persephone A; Vieira, Sarah S; Dumiaty, Yasmina; Phy-Lim, Jenny; Levy, Zachary L; Chee, Melissa J · Animal Study
RPEP-12995 · 2025RAMP3 interacts with the GLP-1 receptor, biasing signaling toward Ca2+ mobilization (away from cAMP), which enhanced glucose-stimulated insulin secretion in pancreatic cells.
Pearce, Abigail; Kumari, Poonam; Sisk, Claudia M; Harris, Matthew; Yeung, Ho Yan; Winfield, Sabrina; Caron, Kathleen M; Ladds, Graham · In Vitro